Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Controlling infectious diseases with Metadichol®

4th World Congress on Infection Prevention and Control

P R Raghavan

Nanorx Inc, USA

Keynote: J Infect Dis Ther

DOI: 10.4172/2332-0877.C1.019

Abstract
Metadichol�® is a nano emulsion of long-chain alcohols found in many foods. It is commonly called Policosanol and is present in foods such as rice, sugar cane, wheat, peanuts. Metadichol�® acts on Nuclear Vitamin D receptors (VDR) that are present in cells throughout the body to stimulate the immune system and inhibit a variety of disease processes, resulting from viral, bacterial and parasitic infections. Gene expression analysis will be presented. We tested Metadichol�® in vitro against viruses and also against malaria, Tb and MRSA. It is the first of a class of unique nano emulsion molecules that are active against viruses, bacteria and parasites. In assays, Metadichol�® showed no cytotoxicity and strongly inhibited cell death caused by each of the pathogen tested. Metadichol�® is a safe and effective inhibitor of various pathogens in humans. Because it consists of natural components of common foods and has no known negative side effects, Metadichol�® has the potential to serve as a novel, broad-spectrum antiviral treatment for viruses, bacteria and parasites that confront public health today.
Biography

P R Raghavan is the CEO of Nanorx Inc, USA. He has completed his PhD in Organic Chemistry from Oregon State University (1979) and MS in Chemistry (1972) from IIT Mumbai, India. He has worked on drug discovery for over 25 years at Columbia University, Max-Planck Institute, Germany, Ciba-Geigy (now Novartis) and 'Boehringer Ingelheim’.

Email: raghavan@nanorxinc.com

Top